Endocrine therapy (ET) is a key treatment modality in the treatment of such estrogen receptor-positive breast cancers and the disruption of the process of estrogen production by inhibition of the peripheral aromatisation (aromatase inhibitors) is a key form of ET [1], Fig. 1. The gene discussed is ESR1; the disease is breast cancer.